Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Merck
Dow
AstraZeneca

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ULORIC

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Uloric

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00102440 Febuxostat Versus Allopurinol Control Trial in Subjects With Gout Completed Takeda Phase 3 2002-07-01 The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.
NCT00174915 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. Completed Takeda Phase 3 2003-02-01 The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.
NCT00174941 Long-Term Safety of Febuxostat in Subjects With Gout. Completed Takeda Phase 2 2001-03-01 The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
NCT00174967 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout Completed Takeda Phase 2 2001-01-01 The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.
NCT00175019 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed Takeda Phase 3 2003-07-01 The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
NCT00430248 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed Takeda Phase 3 2007-02-01 The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Uloric

Condition Name

Condition Name for Uloric
Intervention Trials
Gout 14
Hyperuricemia 4
Hypertension 3
Chronic Kidney Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Uloric
Intervention Trials
Hyperuricemia 8
Gout 8
Renal Insufficiency, Chronic 3
Kidney Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Uloric

Trials by Country

Trials by Country for Uloric
Location Trials
United States 275
Mexico 8
Canada 6
China 2
Iceland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Uloric
Location Trials
Texas 11
Florida 10
California 10
North Carolina 9
Oklahoma 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Uloric

Clinical Trial Phase

Clinical Trial Phase for Uloric
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2 11
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Uloric
Clinical Trial Phase Trials
Completed 19
Not yet recruiting 2
Recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Uloric

Sponsor Name

Sponsor Name for Uloric
Sponsor Trials
Takeda 15
Shanghai 10th People's Hospital 2
Nuon Therapeutics, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Uloric
Sponsor Trials
Industry 20
Other 18
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Mallinckrodt
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.